Abstract: The present disclosure relates to a composition comprising of mangiferin and 7,8,4-trihydroxyisoflavone for increased cellular uptake of glucose, and increased expression of GLUT4. The present disclosure also provides for formulations comprising the same, method of increasing cellular glucose uptake, and expression of GLUT4 by a composition or formulation as mentioned herein.
DESC:A COMPOSITION COMPRISING OF MANGIFERIN AND 7,8,4-TRIHYDROXYISOFLAVONE AND USES THEREOF ,CLAIMS:1. A composition comprising:
a. mangiferin; and
b. 7,8,4-trihydroxyisoflavone.
2. The composition as claimed in claim 1, wherein said composition increases cellular glucose uptake.
3. The composition as claimed in claim 1, wherein said composition increases expression of GLUT4 transcripts.
4. The composition as claimed in claim 1, wherein the mangiferin to 7,8,4-trihydroxyisoflavone w/w ratio in said composition is 6:1-1:1.
5. The composition as claimed in claim 4, wherein the mangiferin to 7,8,4-trihydroxyisoflavone w/w ratio in said composition is 5:1-1.25:1.
6. A formulation comprising a composition as claimed in claim 1.
7. The formulation as claimed in claim 6, further comprising of suitable carriers, diluents, and excipients.
8. The formulation as claimed in claim 6, wherein the mangiferin to 7,8,4-trihydroxyisoflavone w/w ratio in said formulation is 6:1-1:1.
9. The formulation as claimed in claim 8, wherein the mangiferin to 7,8,4-trihydroxyisoflavone w/w ratio in said formulation is 5:1-1.25:1.
10. A method of increasing cellular glucose uptake, said method comprising:
a. obtaining a composition as claimed in claim 1 or a formulation as claimed in claim 6; and
b. contacting said composition or formulation obtained from step (a) with a cell with extracellular glucose.
11. A method of increasing GLUT4 expression, said method comprising:
a. obtaining a composition as claimed in claim 1 or a formulation as claimed in claim 6; and
b. contacting said composition or formulation obtained from step (a) with a cell.
12. A method of preparing a composition as claimed in claim 1 or a formulation as claimed in claim 6.
| Section | Controller | Decision Date |
|---|---|---|
| # | Name | Date |
|---|---|---|
| 1 | 4378-CHE-2013-US(14)-HearingNotice-(HearingDate-18-08-2021).pdf | 2021-10-17 |
| 1 | SPEC IN.pdf | 2013-10-08 |
| 2 | FORM 3.pdf | 2013-10-08 |
| 2 | 4378-CHE-2013-Correspondence to notify the Controller [16-08-2021(online)].pdf | 2021-08-16 |
| 3 | FIGURES IN.pdf | 2013-10-08 |
| 3 | 4378-CHE-2013-CLAIMS [06-03-2020(online)].pdf | 2020-03-06 |
| 4 | 4378-CHE-2013 CORRESPONDENCE OTHERS 20-11-2013.pdf | 2013-11-20 |
| 4 | 4378-CHE-2013-FER_SER_REPLY [06-03-2020(online)].pdf | 2020-03-06 |
| 5 | 4378-CHE-2013-FER.pdf | 2019-09-06 |
| 5 | 4378-CHE-2013 POWER OF ATTORNEY 20-11-2013.pdf | 2013-11-20 |
| 6 | Form 18 [20-01-2017(online)].pdf | 2017-01-20 |
| 6 | 4378-CHE-2013 FORM-1 20-11-2013.pdf | 2013-11-20 |
| 7 | SPEC FOR FILING.pdf | 2014-09-17 |
| 7 | FIG IN.pdf | 2014-09-17 |
| 8 | SPEC FOR FILING.pdf | 2014-09-17 |
| 8 | FIG IN.pdf | 2014-09-17 |
| 9 | Form 18 [20-01-2017(online)].pdf | 2017-01-20 |
| 9 | 4378-CHE-2013 FORM-1 20-11-2013.pdf | 2013-11-20 |
| 10 | 4378-CHE-2013 POWER OF ATTORNEY 20-11-2013.pdf | 2013-11-20 |
| 10 | 4378-CHE-2013-FER.pdf | 2019-09-06 |
| 11 | 4378-CHE-2013 CORRESPONDENCE OTHERS 20-11-2013.pdf | 2013-11-20 |
| 11 | 4378-CHE-2013-FER_SER_REPLY [06-03-2020(online)].pdf | 2020-03-06 |
| 12 | FIGURES IN.pdf | 2013-10-08 |
| 12 | 4378-CHE-2013-CLAIMS [06-03-2020(online)].pdf | 2020-03-06 |
| 13 | FORM 3.pdf | 2013-10-08 |
| 13 | 4378-CHE-2013-Correspondence to notify the Controller [16-08-2021(online)].pdf | 2021-08-16 |
| 14 | SPEC IN.pdf | 2013-10-08 |
| 14 | 4378-CHE-2013-US(14)-HearingNotice-(HearingDate-18-08-2021).pdf | 2021-10-17 |
| 1 | search_04-09-2019.pdf |